Cargando…
The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity
Antibiotic resistance has become a major health issue. Nosocomial infections and the prevalence of resistant pathogenic bacterial strains are rising steadily. Therefore, there is an urgent need to develop new classes of antibiotics effective on multi-resistant nosocomial pathogenic bacteria. We have...
Autores principales: | Heulot, Mathieu, Jacquier, Nicolas, Aeby, Sébastien, Le Roy, Didier, Roger, Thierry, Trofimenko, Evgeniya, Barras, David, Greub, Gilbert, Widmann, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461357/ https://www.ncbi.nlm.nih.gov/pubmed/28638371 http://dx.doi.org/10.3389/fmicb.2017.00994 |
Ejemplares similares
-
The TAT-RasGAP(317-326) anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner
por: Heulot, Mathieu, et al.
Publicado: (2016) -
Assessment of the Chemosensitizing Activity of TAT-RasGAP(317-326) in Childhood Cancers
por: Chevalier, Nadja, et al.
Publicado: (2015) -
Bacterial surface properties influence the activity of the TAT-RasGAP(317-326) antimicrobial peptide
por: Georgieva, Maria, et al.
Publicado: (2021) -
The EnvZ/OmpR Two-Component System Regulates the Antimicrobial Activity of TAT-RasGAP(317-326) and the Collateral Sensitivity to Other Antibacterial Agents
por: Georgieva, Maria, et al.
Publicado: (2022) -
Revisiting G3BP1 as a RasGAP Binding Protein: Sensitization of Tumor Cells to Chemotherapy by the RasGAP 317–326 Sequence Does Not Involve G3BP1
por: Annibaldi, Alessandro, et al.
Publicado: (2011)